{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:32Z","timestamp":1789133132912,"version":"build-2803163510"},"reference-count":58,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T00:00:00Z","timestamp":1446422400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Coinciding with the continually increasing population of immunocompromised patients worldwide, the incidence of invasive fungal infections has grown over the past 4 decades. Unfortunately, infections caused by both yeasts such as <jats:italic>Candida<\/jats:italic> and molds such as <jats:italic>Aspergillus<\/jats:italic> or Mucorales remain associated with unacceptably high morbidity and mortality. In addition, the available antifungals with proven efficacy in the treatment of these infections remain severely limited. Although previously available second\u2010generation triazole antifungals have significantly expanded the spectrum of the triazole antifungal class, these agents are laden with shortcomings in their safety profiles as well as formulation and pharmacokinetic challenges. Isavuconazole, administered as the prodrug isavuconazonium, is the latest second\u2010generation triazole antifungal to receive U.S. Food and Drug Administration approval. Approved for the treatment of both invasive aspergillosis and invasive mucormycosis, and currently under investigation for the treatment of candidemia and invasive candidiasis, isavuconazole may have therapeutic advantages over its predecessors. With clinically relevant antifungal potency against a broad range of yeasts, dimorphic fungi, and molds, isavuconazole has a spectrum of activity reminiscent of the polyene amphotericin B. Moreover, clinical experience thus far has revealed isavuconazole to be associated with fewer toxicities than voriconazole, even when administered without therapeutic drug monitoring. These characteristics, in an agent available in both a highly bioavailable oral and a \u03b2\u2010cyclodextrin\u2013free intravenous formulation, will likely make isavuconazole a welcome addition to the triazole class of antifungals.<\/jats:p>","DOI":"10.1002\/phar.1652","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T07:14:44Z","timestamp":1446448484000},"page":"1037-1051","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent"],"prefix":"10.1002","volume":"35","author":[{"given":"Jeffrey M.","family":"Rybak","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy University of Tennessee Health Science Center Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh R.","family":"Marx","sequence":"additional","affiliation":[{"name":"Division of Pharmacy University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of Tennessee Health Science Center Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. David","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy University of Tennessee Health Science Center Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022139"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"7","author":"Marr KA","year":"2002","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12081"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1315-x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31817eeee5"},{"key":"e_1_2_8_9_1","first-page":"2118\u201331 e1","article-title":"Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991\u20132009","volume":"10","author":"Desai VC","year":"2012","journal-title":"Clin Ther"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-0753-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-14"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00892-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(96)01360-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.06.005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00747-06"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324245111"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-06"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01111-13"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04055-14"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"e_1_2_8_24_1","unstructured":"Astellas Pharma US I.Isavuconazonium NDAs 207500 and 207501 Oral and Intravenous Formulations Anti\u2010Infective Drugs Advisory Committee Briefing Document [government document].2015."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"9","author":"Andes D","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04569-14"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_2_8_31_1","volume-title":"Voriconazole (package insert)","author":"Roerig","year":"2010"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1193-1199.2003"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1179-1186.2003"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-13"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-13"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01279-12"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04586-14"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"12","author":"Pauw B","year":"2008","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"KontoyiannisDP GiladiM LeeM et al.A Phase 3 Randomized Double\u2010Blind Non\u2010Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Conference proceedings ID Week 2014.","DOI":"10.1093\/ofid\/ofu051.99"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1086\/510592"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0456"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","unstructured":"PattersonT SelleslagD MullaneK et al.A Phase 3 Randomized Double\u2010Blind Non\u2010inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients. Conference proceedings ID Week 2014.","DOI":"10.1093\/ofid\/ofu051.98"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","unstructured":"HeinzW CornelyO FranksB ShiF AzieN MaertensJ.A Phase III Randomized Double\u2010Blind Trial to Evaluate Efficacy and Safety of Isavuconazole Versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Hematopoietic Stem Cell Transplant Patients with Invasive Aspergillosis. Conference proceedings 56th American Society of Hematology Annual Meeting and Exposition 2014.","DOI":"10.1182\/blood.V124.21.1133.1133"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1086\/595846"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir866"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12101"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-316430"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2012.711741"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065110"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03176-13"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0552-6"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.256"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1730"},{"key":"e_1_2_8_57_1","volume-title":"Rufinamide tablets (package insert)","author":"Novartis Pharma AG mambEI","year":"2008"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01384-07"},{"key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/JCM.01190-13","article-title":"Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility","volume":"9","author":"Datta K","year":"2013","journal-title":"J Clin Microbiol"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1652","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:08:08Z","timestamp":1761052088000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/phar.1652"],"URL":"https:\/\/doi.org\/10.1002\/phar.1652","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"2015-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}